The essential role of PRAK in tumor metastasis and its therapeutic potential

Metastasis is the leading cause of cancer-related death. Despite the recent advancements in cancer treatment, there is currently no approved therapy for metastasis. The present study reveals a potent and selective activity of PRAK in the regulation of tumor metastasis. While showing no apparent effect on the growth of primary breast cancers or subcutaneously inoculated tumor lines, Prak deficiency abrogates lung metastases in PyMT mice or mice receiving intravenous injection of tumor cells. Consistently, PRAK expression is closely associated with metastatic risk in human cancers. Further analysis indicates that loss of function of PRAK leads to a pronounced inhibition of HIF-1 alpha protein synthesis, possibly due to reduced mTORC1 activities. Notably, pharmacological inactivation of PRAK with a clinically relevant inhibitor recapitulates the anti-metastatic effect of Prak depletion, highlighting the therapeutic potential of targeting PRAK in the control of metastasis. Metastasis is one of the leading causes of cancer-related death. Here, the authors report a pro-metastatic role of PRAK in breast cancer lung metastasis via a mechanism involving enhanced HIF-1 alpha translation, and propose PRAK targeting as a strategy to treat metastasis.

Automated summary

Metastasis is a major cause of cancer-related death. The study demonstrates the significant role of PRAK in regulating tumor metastasis, with Prak deficiency inhibiting lung metastases through a mechanism involving reduced HIF-1 alpha protein synthesis. Targeting PRAK could be a promising strategy in treating metastasis.